Form 4: Immunovant CFO Eva Renee Barnett Reports Stock and Option Transactions

Eva Renee Barnett, CFO of Immunovant, Inc., reports the acquisition of restricted stock units and stock options, as well as the disposal of common stock.

Summary

• On April 1, 2025, Eva Renee Barnett, the Chief Financial Officer of Immunovant, Inc., reported transactions involving Immunovant's common stock and stock options.
• Barnett acquired 88,878 restricted stock units (RSUs) and disposed of 410,830 shares of common stock.
• Additionally, Barnett acquired options to purchase 125,180 shares of common stock at an exercise price of $15.20.
• The RSUs vest as to 25% on April 1, 2026, and the remainder vest quarterly over three years, contingent upon continuous service.
• The stock options also vest as to 25% on April 1, 2026, with the remainder vesting in 36 equal monthly installments over three years, subject to continuous service.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing stock transactions by a company officer, with no inherent positive or negative sentiment.

Future Outlook

The vesting schedules for the RSUs and stock options are contingent upon the Reporting Person's continuous service to the Issuer.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

• The transactions provide transparency to shareholders regarding insider activity.

Key Dates

Keywords

Immunovant, IMVT, Eva Renee Barnett, CFO, Form 4, Stock Options, Restricted Stock Units, Common Stock, Beneficial Ownership, Vesting